Skip to Main Content

WASHINGTON — President Biden’s vision for an ambitious new government research center is never quite the same. He’s said it will focus on diabetes and Alzheimer’s. He told a prominent ALS advocate that the agency would focus on his disease, too. Once, he mentioned obesity. And, of course, there is his most common refrain: that the new research branch will “end cancer as we know it.”

The shifting vision is creating a lobbying frenzy among patient advocacy groups frustrated with the pace of research, all now scrambling to ensure they benefit from the gold rush of new research dollars and high-profile attention.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment